Deep Dive/ Oncology/ Views & Analysis/ Views and analysis Moving from autologous to allogeneic ACT paradigms mike.hammerton@pharmaphorum.com ACT, Acute Lymphocytic Leukaemia, Adoptive Cellular Transfer, CAR T, Deep Dive: Oncology and ASCO 2019, Gilead, ICON, Novartis 0 Comment We have come so far in a relatively short time with Adoptive Cellular Transfer (ACT). The two marketed Share X Moving from autologous to allogeneic ACT paradigms https://pharmaphorum.com/deep-dive/icon-allogeneic-adoptive-cellular-transfer/